Hermetica Superfood Encyclopedia
The Short Answer
Antiaris toxicaria contains potent cardiac glycosides (antiarosides A–I, malayoside, toxicarioside A) and hydroxycinnamate–flavonoid complexes that inhibit Na⁺/K⁺-ATPase, induce cancer cell apoptosis via MAPK-Nur77 and endoglin/TGF-β pathways, and exert cardiotonic effects comparable to ouabain. In vitro cytotoxicity assays demonstrated EC₅₀ values of 61.3–99.9 μg/mL across four human cancer cell lines (MCF-7, THP-1, SW620, AsPC-1) using the hydro-alcoholic aqueous leaf fraction, with complete cytotoxicity (0.1% viability) achieved at 200 μg/mL.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordAntiaris toxicaria benefits
Antiaris — botanical close-up
Health Benefits
**Cytotoxic and Pro-apoptotic Activity**
The hydro-alcoholic aqueous leaf fraction (EHA-Aq) induces dose-dependent apoptosis in breast (MCF-7), leukemia (THP-1), colon (SW620), and pancreatic (AsPC-1) cancer cell lines, with EC₅₀ values ranging from 61.3 to 99.9 μg/mL confirmed by annexin-V labeling; this activity is attributed to cardiac glycosides and hydroxycinnamate compounds.
**Cardiotonic Support**
Cardiac glycosides including antiarosides and malayoside inhibit the Na⁺/K⁺-ATPase pump in cardiac muscle, producing positive inotropic effects analogous to ouabain as demonstrated in ex vivo guinea pig atria preparations; however, this effect carries a narrow therapeutic index.
**Antioxidant Protection**
Methanolic leaf extracts exhibit superior free-radical scavenging activity compared to petroleum ether, benzene, chloroform, and acetone extracts in standard scavenging assays, likely attributable to flavonoids such as the rutin isomer (quercetin glycoside, compound 12) and hydroxycinnamate phenolics identified by UPLC-DAD-QTOF-MS/MS.
**Anti-Tumor Signaling Modulation**
The isolated cardiac glycoside malayoside triggers apoptosis specifically in non-small cell lung cancer via activation of the MAPK-Nur77 signaling cascade, while toxicarioside A suppresses tumor angiogenesis and stromal support by blocking endoglin/TGF-β signaling in bone marrow stromal cells.
**Antimicrobial Activity**
Phytochemical screening of leaves, bark, and latex confirms the qualitative presence of alkaloids, saponins, tannins, flavonoids, and steroids, which collectively confer measurable but relatively low antimicrobial activity against tested bacterial strains compared to other medicinal plants screened in the same studies.
**Traditional Dermatological Use for Small Growths**
In Papua New Guinean Siwai/Buin ethnomedicine, heated seeds are applied topically to small skin growths, representing a documented traditional oncological and dermatological application consistent with the cytotoxic and pro-apoptotic pharmacology identified in modern preclinical research.
**Cytostatic Effects at Sub-Cytotoxic Doses**: At 12
5 μg/mL, EHA-Aq produces a cytostatic effect resulting in a threefold reduction in cancer cell number without full cytotoxicity, suggesting a potential dose-titratable therapeutic window for antiproliferative applications pending further investigation.
Origin & History
Natural habitat
Antiaris toxicaria is a large tropical tree (20–30 m height) native to Southeast Asia, the Pacific Islands, and parts of tropical Africa, thriving in humid lowland and montane rainforests across Indonesia, Papua New Guinea, and sub-Saharan Africa. It grows in diverse forest ecosystems and has been historically exploited for its latex and timber. The species is not cultivated commercially; medicinal and traditional uses rely on wild-harvested bark, seeds, leaves, and latex.
“Antiaris toxicaria holds significant historical notoriety across its range as the source of a potent arrow poison derived from its latex, used by indigenous communities in Southeast Asia and the Pacific Islands for hunting and warfare, a use so pronounced it is reflected in the species epithet 'toxicaria.' In Papua New Guinea, specifically among the Siwai and Buin peoples of Bougainville Island, heated seeds represent a documented ethnomedicinal treatment for small cutaneous growths, situating the plant within a traditional Pacific Islands oncological and dermatological pharmacopoeia. In tropical Africa and Indonesia, various plant parts — bark, leaves, and latex — have been employed in local healing traditions for their perceived cardiotonic, antimicrobial, and wound-healing properties, with the bark's cardiac glycosides likely underpinning observed cardiovascular effects. Modern phytochemical research, building on an ethnobotanical foundation documented partly through the work of Saha et al. (2013), has begun to validate the bioactive rationale for these traditional applications, though the full scope of historical preparation methods and dosing practices remains incompletely recorded.”Traditional Medicine
Scientific Research
The evidence base for Antiaris toxicaria is entirely preclinical, consisting of in vitro cell-line studies, ex vivo tissue assays, and phytochemical characterization analyses, with no published human clinical trials as of the available literature. Key in vitro findings include EC₅₀ values of 63.5 ± 1.8 μg/mL (MCF-7 breast cancer), 64.1 ± 1.8 μg/mL (THP-1 leukemia), 61.3 ± 1.8 μg/mL (AsPC-1 pancreatic cancer), and 99.9 ± 2.0 μg/mL (SW620 colon cancer) for the EHA-Aq leaf fraction, identified via bioassay-guided fractionation and UPLC-DAD-QTOF-MS/MS for compound identification. Cardiotonic bioassays using ex vivo guinea pig atrial preparations confirm Na⁺/K⁺-ATPase inhibition and positive inotropic activity, and bioassay-guided isolation from trunk bark has yielded nine new antiaroside glycosides alongside 18 previously known compounds, providing robust phytochemical characterization. The overall evidence quality is limited by the absence of animal pharmacokinetic studies, toxicology dose-escalation data, and any Phase I–III human trials, making extrapolation to clinical recommendations premature.
Preparation & Dosage
Traditional preparation
**Traditional Topical Application (Siwai/Buin, Papua New Guinea)**
Seeds are heated and applied directly to small skin growths; no standardized preparation protocol, seed quantity, temperature, or application frequency has been documented in the ethnobotanical record.
**Hydro-Alcoholic Aqueous Leaf Extract (Research Grade)**
Prepared by sequential solvent fractionation of methanolic leaf extract; used in vitro at 12.5–200 μg/mL; no human-equivalent dose established.
**Methanolic Leaf Extract (Antioxidant Studies)**
Methanolic extraction yields the highest antioxidant activity among tested solvents; no standardized concentration or human dose defined.
**Ethanolic Trunk Bark Extract (Glycoside Isolation)**
Used for bioassay-guided fractionation to isolate antiarosides A–I and related glycosides; strictly a research preparation, not intended for supplementation.
**Powder Extracts (Solvent Yields)**
Reported extraction yields are very low — petroleum ether 0.89%, benzene 0.92%, chloroform 2.91%, acetone 2.34% — indicating low extractable bioactive content per gram of leaf powder.
**No Established Supplemental Dose**
There is no safe, standardized, or commercially validated supplemental dose for any form of Antiaris toxicaria; all research concentrations are in vitro and carry no direct translational dosing guidance.
Nutritional Profile
Antiaris toxicaria is not recognized as a food or nutritional ingredient and has no established macronutrient or micronutrient profile for human consumption. Leaf powder analysis reveals a moisture content of approximately 7.7% and low total ash values, suggesting minimal mineral contaminant load, but no quantitative data on proteins, carbohydrates, lipids, vitamins, or dietary minerals has been reported. Phytochemically, the most pharmacologically relevant compounds are cardiac glycosides (antiarosides A–I, malayoside, toxicarioside A, antiarotoxinin A) concentrated in bark and seeds, alongside hydroxycinnamates (compounds 2–10, 15–16), a quercetin-3-O-glycoside rutin isomer (compound 12), alkaloids, saponins, tannins, and steroids detected qualitatively in leaves, bark, and latex. Bioavailability of these compounds in humans is entirely unknown, as no pharmacokinetic studies — oral absorption, first-pass metabolism, plasma half-life, or tissue distribution — have been conducted for any fraction or isolate of this species.
How It Works
Mechanism of Action
The primary mechanism of Antiaris toxicaria's bioactivity centers on cardiac glycoside-mediated inhibition of the Na⁺/K⁺-ATPase enzyme in cell membranes, which disrupts intracellular ion homeostasis and triggers downstream apoptotic signaling cascades in both cardiac and malignant cell types. Specifically, the isolated glycoside malayoside activates the MAPK (mitogen-activated protein kinase) pathway to upregulate Nur77, an orphan nuclear receptor that translocates to mitochondria and initiates cytochrome c–dependent apoptosis in non-small cell lung cancer cells, while toxicarioside A selectively antagonizes endoglin (CD105) co-receptor function within the TGF-β signaling complex in bone marrow stromal cells, disrupting tumor-supportive angiogenic signaling. Hydroxycinnamate derivatives and the rutin isomer (quercetin-3-O-glycoside) identified in the leaf fraction contribute to antioxidant and anti-inflammatory activity via direct radical scavenging, inhibition of lipid peroxidation, and potential modulation of NF-κB–dependent inflammatory gene expression. At the cytotoxic level, the combined action of at least three distinct cardiac glycosides and multiple phenolic compounds in EHA-Aq produces synergistic pro-apoptotic effects confirmed by annexin-V externalization assays, achieving >50% cancer cell death at 100 μg/mL across four cell lines.
Clinical Evidence
No human clinical trials have been conducted on Antiaris toxicaria or any of its isolated compounds for any indication, including the traditional Papua New Guinean use of heated seeds for small cutaneous growths. All quantified outcomes derive from in vitro cancer cell line experiments (MCF-7, THP-1, SW620, AsPC-1) and ex vivo guinea pig cardiac tissue preparations, representing early-stage exploratory pharmacology. The most robust in vitro finding is the dose-dependent cytotoxicity of the hydro-alcoholic aqueous leaf fraction across four cancer lines, with EC₅₀ values consistently in the 61–100 μg/mL range, and full cytotoxicity at 200 μg/mL; however, in vitro μg/mL concentrations do not translate directly to human dosing without pharmacokinetic data. Confidence in clinical benefit is very low, and the plant's high cardiac glycoside content introduces significant safety concerns that would require extensive toxicology profiling before any human investigation could be ethically undertaken.
Safety & Interactions
Antiaris toxicaria must be considered highly toxic based on its potent cardiac glycoside content; these compounds (antiarosides, malayoside, toxicarioside A) inhibit Na⁺/K⁺-ATPase with a mechanism and potency analogous to ouabain, which carries an extremely narrow therapeutic index and can cause fatal cardiac arrhythmias, heart block, and hyperkalemia at supratherapeutic doses in humans. No formal toxicology studies, LD₅₀ determinations, NOAEL values, or human safety data have been published for any extract, fraction, or isolated compound from this species, making it impossible to define a safe dose range. Significant drug interactions are anticipated with all cardiac glycoside-sensitizing agents, including antiarrhythmics (amiodarone, quinidine), diuretics causing hypokalemia (furosemide, thiazides), calcium channel blockers, and other positive inotropes; concurrent use would be extremely dangerous. Antiaris toxicaria is absolutely contraindicated in pregnancy, lactation, pediatric populations, and individuals with any cardiac arrhythmia, electrolyte imbalance, or renal impairment; internal consumption in any form is not recommended outside of strictly controlled investigational settings.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Antiaris toxicariaAntiaris africanaUpas treeIpoh treeFalse iroko
Frequently Asked Questions
What is Antiaris toxicaria used for in traditional medicine?
In Papua New Guinean Siwai and Buin ethnomedicine, heated Antiaris toxicaria seeds are applied topically to small skin growths, representing one of the most documented traditional uses in the Pacific Islands. Across Southeast Asia and tropical Africa, bark, leaves, and latex have been used for perceived cardiotonic, antimicrobial, and wound-healing purposes, with modern phytochemistry confirming cardiac glycosides and phenolics as the likely active constituents underlying these traditional applications.
Is Antiaris toxicaria safe to consume or supplement with?
Antiaris toxicaria is not safe for unsupervised human consumption or supplementation; its potent cardiac glycosides (antiarosides A–I, malayoside, toxicarioside A) inhibit Na⁺/K⁺-ATPase with a mechanism identical to ouabain, a compound with a famously narrow therapeutic index capable of causing fatal cardiac arrhythmias. No human toxicology data, safe dose, or standardized supplement form exists, and the plant is contraindicated in pregnant or lactating individuals, those with cardiac conditions, and anyone taking cardiac or diuretic medications.
What bioactive compounds are found in Antiaris toxicaria?
The primary bioactive compounds are cardiac glycosides — including antiarosides A through I, antiarotoxinin A, malayoside, and toxicarioside A — concentrated in trunk bark and seeds and identified via bioassay-guided fractionation. Leaves additionally contain hydroxycinnamates (compounds 2–10 and 15–16) and a quercetin-3-O-glycoside rutin isomer identified for the first time in this species using UPLC-DAD-QTOF-MS/MS, along with alkaloids, saponins, tannins, and steroids detected qualitatively.
Does Antiaris toxicaria have anti-cancer properties?
Preclinical in vitro studies show that the hydro-alcoholic aqueous leaf fraction of Antiaris toxicaria induces dose-dependent apoptosis in MCF-7 breast cancer (EC₅₀ 63.5 μg/mL), THP-1 leukemia (EC₅₀ 64.1 μg/mL), AsPC-1 pancreatic cancer (EC₅₀ 61.3 μg/mL), and SW620 colon cancer (EC₅₀ 99.9 μg/mL) cell lines. However, these are laboratory findings only — no animal studies or human clinical trials have been conducted, and the significant cardiac toxicity of the plant's glycosides presents a major barrier to therapeutic development.
How do the cardiac glycosides in Antiaris toxicaria work?
Cardiac glycosides in Antiaris toxicaria inhibit the Na⁺/K⁺-ATPase ion pump in cell membranes, raising intracellular sodium and calcium levels to produce positive inotropic (heart-strengthening) effects, as confirmed in ex vivo guinea pig atria experiments analogous to ouabain pharmacology. Beyond cardiac effects, the glycoside malayoside induces cancer cell apoptosis via the MAPK-Nur77 signaling pathway, and toxicarioside A blocks endoglin/TGF-β signaling in bone marrow stromal cells, demonstrating targeted anti-tumor mechanisms at the molecular level.
What is the difference between Antiaris toxicaria leaf extract and whole leaf preparations?
Leaf extracts, particularly hydro-alcoholic aqueous fractions (EHA-Aq), concentrate bioactive compounds like cardiac glycosides and hydroxycinnamates to standardized levels, whereas whole leaf preparations contain these compounds in lower, variable concentrations. Standardized extracts demonstrate measurable cytotoxic activity in laboratory studies with consistent EC₅₀ values (61.3–99.9 μg/mL across cancer cell lines), while whole leaf efficacy is less predictable and reproducible. The extraction process significantly enhances the potency and consistency of the active constituents responsible for pro-apoptotic effects.
Why is Antiaris toxicaria considered potentially hazardous compared to other herbal supplements?
Antiaris toxicaria contains potent cardiac glycosides—the same class of compounds found in digitalis that can cause severe toxicity at even small dose variations—making the margin between therapeutic and toxic levels extremely narrow. Its traditional use as an arrow poison and the lack of established safe dosage parameters in modern supplementation increase risk significantly compared to herbs with longer histories of regulated human use. The cytotoxic properties that make it interesting for cancer research in controlled laboratory settings represent a serious safety concern in uncontrolled supplement form.
What does current research suggest about Antiaris toxicaria's effectiveness against different cancer types?
Laboratory studies show that Antiaris toxicaria leaf extract induces dose-dependent apoptosis (programmed cell death) across multiple cancer cell lines, including breast (MCF-7), leukemia (THP-1), colon (SW620), and pancreatic (AsPC-1) cancers, with consistent EC₅₀ values between 61.3 and 99.9 μg/mL. However, all current evidence is limited to in vitro (test tube) studies using isolated cell lines, with no human clinical trials published to date. The transition from cell-based research to proven human efficacy and safety remains unestablished, making any therapeutic claims premature.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w antiaris-antiaris-toxicaria curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
